# Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

> **NCT02406014** · PHASE4 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 502 (actual)

## Conditions studied

- Actinic Keratosis (AK)

## Interventions

- **DRUG:** Ingenol Mebutate Gel, 0.015%
- **DRUG:** Diclofenac sodium gel 3%

## Key facts

- **NCT ID:** NCT02406014
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02406014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02406014, "Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02406014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*